A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer.
NCT06746545
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
30
Enrollment
OTHER_GOV
Sponsor class
Conditions
Colorectal Cancer
Interventions
DRUG:
Fruquintinib+S-1
Sponsor
Fujian Cancer Hospital